New Active Substances (NAS) LAUNCHED DURING 2018

May 16, 2018

Next up in the Annual Pharma R&D Review, the NAS supplement takes a look at the industry’s victories of 2018 – the drugs launched on to the market for the first time. New entities where the active ingredient had received no prior approval for human use are the focus of this roster of drugs which successfully crossed the finishing line, and lifted the trophy, to become part of pharma’s elite 2018 team.

Spotlight

Medicines for Europe

Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio. As the pharmaceutical industry and the healthcare environment within which it operates have evolved, so has our Association. When the association was first launched back in 1993, generic alternatives to branded medicines made up a fraction of the market. As more of these medicines came off-patent, and the benefits and value of generics to both patients and healthcare providers became clearer, so the provision of generic medicines has increased dramatically.

Other Infographics
news image

Summary of Chloroquine and Hydroxychloroquine Drug-Drug Interactions

Infographic | April 7, 2020

COVID-19 is a rapidly emerging and devastating pandemic disease. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested for possible off-label use for patients suffering from a more severe clinical course.

Read More
news image

Latest Improvement on Pharmanews to Serve You Better

Infographic | April 16, 2020

Poised to give our readers and advertisers better services in spite of the COVID19 pandemic, Pharmanews–your global health journal has continued to improve on its services in terms of healthcare information dissemination, by keeping readers abreast of latest development in public health, especially on how to stay safe from the novel Coronavirus, as well as expanding our reach to over 250,000 readers per month.

Read More
news image

Smart Pharmacovigilance

Infographic | May 23, 2021

Pharmacovigilance (PV) is essential to all life science organizations, ensuring that patients' health comes first. Various trends in global healthcare have transformed today’s PV function into a corporate asset that enhances brand value and contributes to new growth opportunities. However, existing safety systems impose a significant cost burden to operate.

Read More
news image

Cancer Drugs Bring in Most Pharma Revenue

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Read More
news image

2021 global life sciences outlook

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

Read More
news image

What Does The Pharma IndustryWant From CROs?

Infographic | June 16, 2022

Use Informa Pharma Intelligence’s marketing and pharma expertise to conduct industry research, produce engaging thought leadership content,

Read More

Spotlight

Medicines for Europe

Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio. As the pharmaceutical industry and the healthcare environment within which it operates have evolved, so has our Association. When the association was first launched back in 1993, generic alternatives to branded medicines made up a fraction of the market. As more of these medicines came off-patent, and the benefits and value of generics to both patients and healthcare providers became clearer, so the provision of generic medicines has increased dramatically.

Events